{"id":"NCT00855920","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study Utilizing Rilonacept in Gout Exacerbations","officialTitle":"A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2009-03-05","resultsPosted":"2017-04-28","lastUpdate":"2017-04-28"},"enrollment":225,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Gout Flare"],"interventions":[{"type":"DRUG","name":"Rilonacept","otherNames":[]},{"type":"DRUG","name":"Indomethacin","otherNames":[]},{"type":"OTHER","name":"Placebo (for Indomethacin)","otherNames":[]},{"type":"OTHER","name":"Placebo (for Rilonacept)","otherNames":[]}],"arms":[{"label":"Placebo (for Rilonacept) and Indomethacin","type":"ACTIVE_COMPARATOR"},{"label":"Rilonacept and Indomethacin","type":"ACTIVE_COMPARATOR"},{"label":"Rilonacept and Placebo (for Indomethacin)","type":"ACTIVE_COMPARATOR"}],"summary":"This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.","primaryOutcome":{"measure":"Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours","timeFrame":"Pre-dose on Day 1 (Baseline); post-dose at 4, 8, 12, 24, 48, 72 hours and then daily up to Day 13 or until gout flare ends","effectByArm":[{"arm":"Placebo (for Rilonacept) and Indomethacin","deltaMin":-1.4,"sd":0.956},{"arm":"Rilonacept and Indomethacin","deltaMin":-1.55,"sd":0.919},{"arm":"Rilonacept and Placebo (for Indomethacin)","deltaMin":-0.69,"sd":0.97}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":["23375025"],"seeAlso":["http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=501081761&QV1=RILONACEPT","http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?objectHandle=DBMaint&APPLICATION_NAME=drugportal&mergeData=true&actionHandle=default&nextPage=jsp%2Fdrugportal%2FResultScreen.jsp%3FprevPage%3Djsp%2Fdrugportal%2FChemidDataview.jsp%26OriginalSearc"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["Headache","Dizziness"]}}